Portfolio Lab

Harmony Biosciences Holdings, Inc.

  • Stock
  • Ticker HRMY
  • Nasdaq

Health care · Pharmaceuticals · USA

$32.59 −1.18%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Harmony Biosciences Holdings, Inc. since 08/2020, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

HRMYGlobal equities (VT)

$10,000 grew to $7,859. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −68.5% in 10/2023, measured from the peak in 12/2022. The old peak has not been reached again yet.

1-year return
−2.4%
5-year return p.a.
−3.4%
Return p.a. since 08/2020
−2.0%
Volatility p.a.
43.8%
Largest decline
−68.5%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue201185200239244215261269
Gross profit147153162180175171198188
Operating income5656486539378954
EBITDA56564865–378954
Net income4946405122327548
Earnings per share0.850.780.680.870.390.551.280.81
Balance sheet
Total assets9991,0561,1081,2081,2721,2721,3731,478
Liabilities340335335373401361374406
Equity6597217738358709109991,072
Cash453489546647753589550647
Long-term debt163158153149144139134129
Cash flow
Operating cash flow763479109126289277
Capital expenditure-0.5-0.10.0-0.1-0.1–––
Free cash flow753479109126289277

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2022 at +29.2%, weakest 2023 at −41.4%. 4 of 5 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
4 Nov 2026$0.81
4 Aug 2026$1.28
7 May 2026$0.55
24 Feb 2026$0.39
4 Nov 2025$0.87
5 Aug 2025$0.68
6 May 2025$0.78
25 Feb 2025$0.85
29 Oct 2024$0.79
6 Aug 2024$0.20
30 Apr 2024$0.67
22 Feb 2024$0.45

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.7bn
Market cap in trading currency
$1.91bn
Enterprise value
$1.29bn
P/E
10.8
P/S
1.93
P/B
1.78
EV/Sales
1.31
EV/EBITDA
–
Earnings yield
9.3%
FCF yield
16.9%

Results (last four quarters)

Revenue
$989m
Gross profit
$732m
EBITDA
–
Net income
$179m
Earnings per share
$3.03
Revenue per share
$16.85
Revenue growth
+12.3%
Earnings growth
−5.2%

Profitability

Gross margin
74.0%
Operating margin
22.2%
Net margin
18.1%
Return on equity
18.7%
Return on assets
12.1%

Balance sheet and cash flow

Cash
$771m
Cash per share
$13.13
Financial debt
$149m
Debt/equity %
14
Current ratio
3.44
Book value per share
$18.26
Operating cash flow
$323m
Free cash flow
$323m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
58.7m
Volume
582,620
Avg. volume 3 months
1.01m
Relative volume
0.6

Price and technicals

Price
$32.59
1 day
−1.2%
52-week high
$42.86
52-week low
$26.54
Distance to 52-week high
−24.0%
Distance to 52-week low
+22.8%
Distance to 50-day line
−13.7%
Distance to 200-day line
−5.4%
RSI (14)
32
Volatility 1M
40.3%

Performance

1 week
−3.5%
1 month
−9.5%
3 months
−15.4%
6 months
+8.1%
YTD
−12.9%
1 year
−2.2%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has HRMY performed since 08/2020?

$10,000 grew to $8,806 by 20 Nov 2026, which is −2.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is HRMY?

Volatility was 43.8% per year, measured on monthly returns. The largest decline from a peak was −68.5%, with the low in 10/2023.

How does HRMY compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.4% per year at 15.1% volatility, HRMY returned −2.0% at 43.8%. The correlation of monthly returns was 0.30; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Harmony Biosciences Holdings, Inc. (HRMY): Return and risk